|
1）Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009; 147: 43-70
|
|
|
|
2）Scheinberg P, Nunez O, Wu C, et al. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol. 2006; 133: 606-11
|
|
|
|
|
|
3）Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009; 94: 348-54
|
|
|
|
|
|
4）Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood. 1996; 87: 491-4
|
|
|
|
|
|
5）Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. Ann Intern Med. 2001; 135: 477-83
|
|
|
|
|
|
6）Brodsky RA, Chen AR, Brodsky I, et al. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol. 2004; 32: 435-40
|
|
|
|
|
|
7）Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010; 115: 2136-41
|
|
|
|
|
|
8）Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000; 356: 1554-9
|
|
|
|
|
|
9）Tisdale JF, Maciejewski JP, Nunez O, et al. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood. 2002; 100: 4668-70
|
|
|
|
|
|
10）Zhanga F, Zhanga L, Jinga L, et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol. 2013; 41: 328-34
|
|
|
|
|
|
11）Scheinberg P, Townsley D, Dumitriu B, et al. Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood. 2014; 124: 2820-3
|
|
|
|
|
|
12）Liu Q, Zhao X, Xu N, et al. Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin. Br J Haematol. 2015 Mar 30. doi: 10.1111/bjh.13396. [Epub ahead of print]
|
|
|
|
|
|
13）Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367: 11-9
|
|
|
|
|
|
14）de Latour RP. Cyclophosphamide in severe aplastic anemia? Blood. 2014; 124: 2758-9
|
|
|
|
|
|
15）Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015 Jul 28. doi: 10.1111/bjh.13614. [Epub ahead of print]
|
|
|
|
|
|
16）DeZern AE, Luznik L, Fuchs EJ, et al. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2011; 46: 1012-3
|
|
|
|
|